InvestorsHub Logo
Followers 829
Posts 119628
Boards Moderated 14
Alias Born 09/05/2002

Re: vinmantoo post# 1953

Thursday, 05/06/2021 6:58:25 PM

Thursday, May 06, 2021 6:58:25 PM

Post# of 2961

Is a 1-log decrease going to be sufficient to be a good anti-HBV drug?

These were nuke-suppressed patients, so their viral-load levels for both DNA and RNA were already very low at baseline.

We’ll get a read on the viral-load-reducing efficacy of EDP-514 in the separate trial in viremic patients.

I assume ENTA won't be using EDP-514 as a single drug treatment.

Correct. A three-drug combination is probably going to be necessary for a functional cure. ENTA will eventually test EDP-514 + EDP-721 + nuke, aiming for an all-oral functional cure that no other company is attempting, as far as I know.

I guess we have to see how the 800mg dosage does.

The 400mg and 200mg doses showed good coverage at trough (24-hour) levels, so it’s not clear that 800mg will be better.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News